The North America Protein A Resin Market would witness market growth of 5.5% CAGR during the forecast period (2022-2028).
Due to the high affinity & selectivity of protein A resins, 99% purity could be obtained in the most generic form. Modification in the construction of the native Protein A, like multiple binding sites and single domain multimer, results in high binding capacity, good physicochemical stability, and high specificity towards the Fc region of antibodies.
The changed components have led to the development of a highly stable and robust protein. A affinity resin, largely utilized in immunology & biotechnology researches for purification processes and downstream processing. Protein A resin is connected with various base metrics like hydrogel filled into a ceramic shell, coated polystyrene, surface-modified porous glass, cross-linked agarose, and multiple materials based on organic polymers.
Protein A chromatography resin is essential for the purification procedure. It enables stringent purity levels throughout the purification of therapeutics antibodies. For instance, it allows the elimination of impurities and decreases the host cell proteins to <100 ppm and DNA to <10 pg per dose.
In 2021, Mexico imported USD 5.9 billion in medical supplies and devices and a total of USD 5.2 billion in pharmaceutical goods. The 2022 budget planning of Mexico comprises a 14.6% growth in health segment resources that gives preference to first and second-level treatment for high-specialty disorders, like cancer, heart disease, and diabetes.
Government healthcare organizations account for 70–80% of all medical facilities provided throughout the nation, whereas private healthcare organizations serve nearly 25–30% of the population. This comprises the overlap between the two facilities and contains the 32 million people with accident insurance and private medical. An increase in cancer patients and improvement in the healthcare sector across the region accelerate the use and production of protein A resins, thereby leading to regional market growth.
The US market dominated the North America Protein A Resin Market by Country 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $545.3 million by 2028.The Canada market is poised to grow at a CAGR of 7.9% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 6.9% during (2022 - 2028).
Based on Product Type, the market is segmented into Agarose-based, Glass/Silica-based and Organic Polymer-based. Based on End Use, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Academic Research Institutes and Others. Based on Type, the market is segmented into Recombinant and Natural. Based on Application, the market is segmented into Antibody Purification and Immunoprecipitation. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Protein A Resin Market is Estimated to reach $1.9 Billion by 2028, at a CAGR of 6.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include General Electric (GE) Co. (GE Healthcare), Repligen Corporation, PerkinElmer, Inc, Thermo Fisher Scientific, Inc., Merck Millipore (Merck Group), Genscript Biotech Corporation, Agilent Technologies, Inc., Abcam plc, and Novasep Holdings SAS (Azulis Capital).
By Product Type
By End Use
By Type
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
